Blueprint Medicines Corp (NASDAQ:BPMC) price remained unchanged from its previous close.
A look at the daily price movement shows that the last close reads $127.97. Taking into account the 52-week price action we note that the stock hit a 52-week high of $128.24 and 52-week low of $73.04. The stock added 31.70% on its value in the past month.
On average, analysts have forecast the company’s revenue for the quarter will hit 171.34M, with the likely lows of 165.1M and highs of 180.1M. The average estimate suggests sales growth for the quarter will likely rise by 24.01% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of 720.59M for the company’s annual revenue in current year. Per this projection, the revenue is forecast to grow 41.62% above that which the company brought in the current year earning report.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 10 analysts have assigned BPMC a recommendation rating as follows: 4 rate it as a Hold; 6 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Blueprint Medicines Corp (BPMC) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that BPMC’s price is at present 16.30% off the SMA20 and 31.61% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 76.16, with weekly volatility standing at 0.10%. The indicator jumps to 5.71% when calculated based on the past 30 days. Blueprint Medicines Corp (NASDAQ:BPMC)’s beta value is holding at 0.84, while the average true range (ATR) indicator is currently reading 3.78. Considering analysts have assigned the stock a price target range of $132-$150 as the low and high respectively, we find the trailing 12-month average consensus price target to be $141. Based on this estimate, we see that current price is roughly -3.15% off the estimated low and -17.21% off the forecast high. Investors will no doubt be excited to see the share price fall to $141, which is the median consensus price, and at that level BPMC would be -10.18% from current price.
Current records show that the company has 64.56M in outstanding shares. The insiders’ percentage holdings are 3.67% of outstanding shares while the percentage share held by institutions stands at 106.96%. But the 46.72% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
